Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration

• Autor(a) principal: Nunes,Renata Portella
• Data de Publicação: 2019
• Outros Autores: Hirai,Flávio Eduardo, Barroso,Letícia Fernandes, Badaró,Emmerson, Novais,Eduardo, Rodrigues,Eduardo Buchele, Maia,Mauricio, Magalhães Jr.,Octaviano, Farah,Michel Eid
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos brasileiros de oftalmologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492019000300011
• topic: Macular degeneration; Retina; Bevacizumab; Ranibizumab; Clinical trial

ABSTRACT Purpose: To study the efficacy and safety of treatments with ranibizumab and bevacizumab for exudative age-related macular degeneration. Methods: A parallel randomized clinical trial was conducted to compare the efficacy and safety of three regimens (bevacizumab every month, bevacizumab every 2 weeks, and ranibizumab every month), followed by as-needed retreatments, for 1 year, in previously untreated individuals with age-related macular degeneration. The primary outcome was change in visual acuity and in central macular thickness after 1 year of follow-up. Subjects were assigned randomly to one of the three groups in a 1:1:1 ratio, and investigators and examiners were blinded to the randomization results. Results: We included 15 patients in each group. After 1 year of follow-up, we found statistically significant improvements in visual acuity and central macular thickness reduction in all groups. However, we found no statistically significant differences between the three groups. Conclusions: The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.